Compare Bit Digital Inc (BTBT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bit Digital Inc vs Crispr Therapeutics AG — how do they compare? Bit Digital Inc trades at $1.45 (market cap $471.05M), while Crispr Therapeutics AG trades at $53.93 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 11.1× Bit Digital Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BTBT | CRSP | |
|---|---|---|
Market Cap | $471.05M | $5.23B |
Sector | Technology | Health |
52-Week High | $4.22 | $76.78 |
52-Week Low | $1.23 | $44.34 |
Enterprise Value | $760.36M | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.485, up 14.23% in the last 24 hours, but remains in a bearish technical trend. The company reported a net loss of $80.32 million on $113.56 million revenue for 2025, with a negative net income margin of -145.45%. Recent earnings have missed expectations, though analyst consensus is a Buy with a $5.12 average price target.
The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing activities. Key risks include execution on profitability and market volatility. The stock presents a high-risk opportunity contingent on the company's ability to reverse its negative earnings trend.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
